Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ABCL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAbCellera prices $200M equity offering to fund ABCL635 clinical development
Filed August 13, 2026 · Period ending August 12, 2026 · ~1 min read
Key Changes
-
high
AbCellera entered into an underwriting agreement for a public offering of 17.4M common shares at $9.75 and 3.1M pre-funded warrants at $9.74999, expecting net proceeds of ~$187M after fees.
Item 1.01 verify on EDGAR → -
high
Net proceeds will fund clinical advancement of the internal pipeline, specifically lead program ABCL635, plus working capital and general corporate purposes.
Exhibit 99.1 view on EDGAR → -
medium
Pre-funded warrants are immediately exercisable at $0.00001 per share with a 4.99% beneficial ownership cap (adjustable to 19.99% with 61 days' notice).
Item 1.01 verify on EDGAR → -
medium
The company, executive officers, and directors agreed to a 60-day lock-up period preventing share sales following August 12, 2026, subject to certain exceptions.
Item 1.01 verify on EDGAR → -
low
The offering closed on or about August 14, 2026, under a shelf registration statement filed in February 2025.
Item 1.01 verify on EDGAR →
Summary
AbCellera completed a $200 million public equity offering on August 12, 2026, selling 17.4 million common shares at $9.75 and 3.1 million pre-funded warrants at $9.74999. The offering was oversubscribed and underwritten by Jefferies and J.P. Morgan. After deducting underwriting fees and expenses, the company expects to net approximately $187 million.
The proceeds are earmarked for clinical development of AbCellera's internal pipeline, with specific focus on advancing ABCL635, the company's lead clinical program. The remainder will support working capital and general corporate purposes.
The pre-funded warrants are structured as near-equity instruments, exercisable immediately at a nominal $0.00001 per share, effectively functioning as common shares with a beneficial ownership cap. For retail holders, this is a material dilutive event—the 20.5 million shares and warrant shares represent a meaningful increase to the share count. The 60-day insider lock-up provides some near-term selling pressure relief, but the capital raise signals the company needs external funding to advance its pipeline rather than relying on existing cash or partnership revenues.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company estimates that the net proceeds from the offering will be approximately $187.0 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
The company expects to receive approximately $187.0 million in net proceeds from the offering after deducting underwriting fees and expenses. The filing does not specify how the proceeds will be used.
Added in current filing · verify on EDGAR →
In addition, subject to certain exceptions, the Company and its executive officers and directors have agreed not to offer, sell, transfer or otherwise dispose of any shares of common stock during the 60-day period following the date of the Underwriting Agreement.
The company, its executive officers, and directors have agreed to a 60-day lock-up period following August 12, 2026, during which they cannot sell or transfer common stock, subject to certain exceptions. This is a standard provision to prevent immediate selling pressure following the offering.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The closing of the offering is expected to take place on or about August 14, 2026, subject to the satisfaction of customary closing conditions.
The offering is expected to close on or about August 14, 2026, subject to customary closing conditions. The shares and warrants are being issued under a shelf registration statement filed in February 2025.
Event · Item 8.01 — Other Events
AbCellera announced the pricing of an offering on August 12, 2026.
Added in current filing · verify on EDGAR →
On August 12, 2026, the Company announced the pricing of the offering.
AbCellera disclosed that it announced the pricing of an offering on August 12, 2026. The 8-K does not provide details on the type of offering, the pricing terms, the size, or the use of proceeds. The press release referenced in Exhibit 99.1 would contain those material details, but the exhibit text is not included in the filing body provided.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
AbCellera Biologics Inc. (Nasdaq: ABCL) (“AbCellera”) today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares at a price to the public of $9.74999 per pre-funded warrant, which represents the per share public offering price of each common share less the $0.00001 per share exercise price for each pre-funded warrant. The gross proceeds to AbCellera from the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
AbCellera priced an oversubscribed public offering of 17,435,897 common shares at $9.75 per share and pre-funded warrants for 3,076,926 shares at $9.74999 per warrant. The company expects gross proceeds of approximately $200 million before fees and expenses. The offering is scheduled to close on August 14, 2026.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 14, 2026 · How we verify